370 related articles for article (PubMed ID: 16855372)
1. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
Cai L; Uchiyama H; Yanagisawa S; Kamae I
Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
3. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over.
Kelly H; Attia J; Andrews R; Heller RF
Vaccine; 2004 Jun; 22(17-18):2192-8. PubMed ID: 15149776
[TBL] [Abstract][Full Text] [Related]
4. [Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].
Postma MJ; Heijnen ML; Beutels P; Jager JC
Ned Tijdschr Geneeskd; 2002 May; 146(18):855-9. PubMed ID: 12038224
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
Melegaro A; Edmunds WJ
Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
[TBL] [Abstract][Full Text] [Related]
6. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
7. Could a federal program to promote influenza vaccination among elders be cost-effective?
Patel MS; Davis MM
Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
[TBL] [Abstract][Full Text] [Related]
8. [An economic evaluation of strategy for expanding influenza vaccination in Japan].
Hara Y
Nihon Rinsho; 2003 Nov; 61(11):2013-8. PubMed ID: 14619447
[TBL] [Abstract][Full Text] [Related]
9. Policy evaluation for the subsidy for influenza vaccination in elderly.
Ohkusa Y
Vaccine; 2005 Mar; 23(17-18):2256-60. PubMed ID: 15755606
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan.
Hoshi SL; Kondo M; Honda Y; Okubo I
Vaccine; 2007 Aug; 25(35):6511-21. PubMed ID: 17681651
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
[TBL] [Abstract][Full Text] [Related]
12. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
[TBL] [Abstract][Full Text] [Related]
13. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community.
Praditsuwan R; Assantachai P; Wasi C; Puthavatana P; Kositanont U
J Med Assoc Thai; 2005 Feb; 88(2):256-64. PubMed ID: 15962680
[TBL] [Abstract][Full Text] [Related]
16. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines.
Fiebach N; Beckett W
Arch Intern Med; 1994 Nov; 154(22):2545-57. PubMed ID: 7979851
[TBL] [Abstract][Full Text] [Related]
17. [Study on the effectiveness and cost-benefit of influenza vaccine on elderly population in Beijing city].
Liu M; Liu GF; Wang Y; Zhao W; Wang L; Shi W; Wen SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2005 Jun; 26(6):412-6. PubMed ID: 16185449
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacoeconomics of vaccinations in chronic obstructive pulmonary disease].
Słominski JM; Kubiak A
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():83-5. PubMed ID: 15524025
[TBL] [Abstract][Full Text] [Related]
20. Reducing medical service utilization by encouraging vaccines: randomized controlled trial.
Berg GD; Thomas E; Silverstein S; Neel CL; Mireles M
Am J Prev Med; 2004 Nov; 27(4):284-8. PubMed ID: 15488357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
